Literature DB >> 2567936

Ceftriaxone-associated biliary pseudolithiasis in adults.

C Pigrau, A Pahissa, S Gropper, D Sureda, J M Martinez Vazquez.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2567936     DOI： 10.1016/s0140-6736(89)90228-6

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  13 in total

1.  Acute necrotizing cholecystitis: a rare complication of ceftriaxone-associated pseudolithiasis.

Authors:  Sendia Kim; Kathleen M Gura; Mark Puder
Journal:  Pediatr Surg Int       Date:  2006-02-17       Impact factor: 1.827

2.  A symptomatic child with ceftriaxone-associated biliary pseudolithiasis.

Authors:  Naoki Kutuya; Yutaka Ozaki; Tadaharu Okazaki
Journal:  J Med Ultrason (2001)       Date:  2008-09-19       Impact factor: 1.314

Review 3.  Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections.

Authors:  Harriet M Lamb; Douglas Ormrod; Lesley J Scott; David P Figgitt
Journal:  Drugs       Date:  2002       Impact factor: 9.546

4.  Ceftriaxone-induced pseudolithiasis in children treated for perforated appendicitis.

Authors:  Hanna Alemayehu; Amita A Desai; Priscilla Thomas; Susan W Sharp; Shawn D St Peter
Journal:  Pediatr Surg Int       Date:  2014-01-28       Impact factor: 1.827

5.  Randomized trial comparing ceftriaxone with cefonicid for treatment of spontaneous bacterial peritonitis in cirrhotic patients.

Authors:  J Gómez-Jiménez; E Ribera; I Gasser; M A Artaza; O Del Valle; A Pahissa; J M Martínez-Vázquez
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

Review 6.  Adverse effects of newer cephalosporins. An update.

Authors:  J W Thompson; R F Jacobs
Journal:  Drug Saf       Date:  1993-08       Impact factor: 5.606

Review 7.  Drug-induced gallbladder disease. Incidence, aetiology and management.

Authors:  P P Michielsen; H Fierens; Y M Van Maercke
Journal:  Drug Saf       Date:  1992 Jan-Feb       Impact factor: 5.606

8.  Risk factors of ceftriaxone-associated biliary pseudolithiasis in adults: influence of renal dysfunction.

Authors:  Aya Imafuku; Naoki Sawa; Akinari Sekine; Masahiro Kawada; Rikako Hiramatsu; Masayuki Yamanouchi; Eiko Hasegawa; Noriko Hayami; Jyunichi Hoshino; Yoshifumi Ubara; Kenmei Takaichi
Journal:  Clin Exp Nephrol       Date:  2017-10-12       Impact factor: 2.801

9.  Reversible Ceftriaxone-Induced Pseudolithiasis in an Adult Patient with Maintenance Hemodialysis.

Authors:  Aya Shima; Takaichi Suehiro; Misaki Takii; Hiroyasu Soeda; Makoto Hirakawa
Journal:  Case Rep Nephrol Dial       Date:  2015-09-18

10.  Progressive Pseudolithiasis Associated with the Intravenous Administration of Ceftriaxone in Patients with Central Nervous System Infections.

Authors:  Setsuki Tsukagoshi; Kunihiko Ishizawa; Kimitoshi Hirayanagi; Shun Nagamine; Kouki Makioka; Yukio Fujita; Yoshio Ikeda
Journal:  Intern Med       Date:  2017-10-11       Impact factor: 1.271
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.